BiotechTube

Duloxetine Hydrochloride + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depressive Disorder

Conditions

Depressive Disorder

Trial Timeline

Dec 4, 2017 → Nov 8, 2019

NCT ID
NCT03315793

About Duloxetine Hydrochloride + Placebo

Duloxetine Hydrochloride + Placebo is a phase 3 stage product being developed by Shionogi for Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03315793. Target conditions include Depressive Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03315793Phase 3Completed

Competing Products

20 competing products in Depressive Disorder

See all competitors
ProductCompanyStageHype Score
duloxetineEli LillyPre-clinical
23
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
Duloxetine HydrochlorideShionogiPhase 3
77
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85